SpringerLink
Log in

NAFLD and Statins

  • Correspondence
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Labenz C, Huber Y, Michel M, et al. Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany. Dig Dis Sci. 2019;65:2112–2119. https://doi.org/10.1007/s10620-019-05986-9

    Article  Google Scholar 

  2. Athyros VG, Kakafika AI, Papageorgiou AA, et al. GREACE Study Collaborative Group. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids. 2007;42:999–1009.

    Article  CAS  Google Scholar 

  3. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013;168:3846–3852.

    Article  Google Scholar 

  4. Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21:7860–7868.

    Article  CAS  Google Scholar 

  5. Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705–712.

    Article  CAS  Google Scholar 

  6. Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism. 2017;71:17–32.

    Article  CAS  Google Scholar 

  7. Nayak A, Hayen A, Zhu L, et al. Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. BMJ Open. 2018;8:e020584.

    Article  Google Scholar 

  8. Orkaby AR, Driver JA, Ho YL, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA. 2020;324:68–78.

    Article  CAS  Google Scholar 

  9. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–380.

    Article  Google Scholar 

  10. Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020;5:31–41.

    Article  Google Scholar 

  11. Labenz C, Huber Y, Kalliga E, et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther. 2018;48:1109–1116.

    Article  CAS  Google Scholar 

  12. Labenz C, Prochaska JH, Huber Y, et al. Cardiovascular risk categories in patients with nonalcoholic fatty liver disease and the role of low-density lipoprotein cholesterol. Hepatol Commun. 2019;3:1472–1481.

    Article  CAS  Google Scholar 

  13. Lazarus JV, Colombo M, Cortez-Pinto H, et al. NAFLD—sounding the alarm on a silent epidemic. Nat Rev Gastroenterol Hepatol. 2020;17:377–379.

    Article  Google Scholar 

  14. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.

    Article  Google Scholar 

  15. Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study. J Hepatol. 2018;68:476–484.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Aristotle University of Thessaloniki, Marmara 15, 55132, Thessaloníki, Greece

    Vasilios G. Athyros & Niki Katsiki

  2. Department of Clinical Biochemistry, Royal Free Hospital, University College London, London, UK

    Dimitri P. Mikhailidis

Authors
  1. Vasilios G. Athyros
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niki Katsiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitri P. Mikhailidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasilios G. Athyros.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Athyros, V.G., Katsiki, N. & Mikhailidis, D.P. NAFLD and Statins. Dig Dis Sci 65, 3052–3053 (2020). https://doi.org/10.1007/s10620-020-06505-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-020-06505-x

Search

Navigation